108 related articles for article (PubMed ID: 21275050)
1. Tetrahydrobenzothiophene derivatives: conformationally restricted inhibitors of type II dehydroquinase.
Paz S; Tizón L; Otero JM; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Lapthorn AJ; Castedo L; González-Bello C
ChemMedChem; 2011 Feb; 6(2):266-72. PubMed ID: 21275050
[No Abstract] [Full Text] [Related]
2. Competitive inhibitors of Helicobacter pylori type II dehydroquinase: synthesis, biological evaluation, and NMR studies.
Sánchez-Sixto C; Prazeres VF; Castedo L; Suh SW; Lamb H; Hawkins AR; Cañada FJ; Jiménez-Barbero J; González-Bello C
ChemMedChem; 2008 May; 3(5):756-70. PubMed ID: 18200648
[TBL] [Abstract][Full Text] [Related]
3. Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors.
Payne RJ; Peyrot F; Kerbarh O; Abell AD; Abell C
ChemMedChem; 2007 Jul; 2(7):1015-29. PubMed ID: 17487900
[TBL] [Abstract][Full Text] [Related]
4. Rational design of new bifunctional inhibitors of type II dehydroquinase.
Toscano MD; Stewart KA; Coggins JR; Lapthorn AJ; Abell C
Org Biomol Chem; 2005 Sep; 3(17):3102-4. PubMed ID: 16106291
[TBL] [Abstract][Full Text] [Related]
5. 2-substituted-3-dehydroquinic acids as potent competitive inhibitors of type II dehydroquinase.
Prazeres VF; Castedo L; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2009 Dec; 4(12):1980-4. PubMed ID: 19856378
[No Abstract] [Full Text] [Related]
6. Determination of the bound conformation of a competitive nanomolar inhibitor of mycobacterium tuberculosis type II dehydroquinase by NMR spectroscopy.
Prazeres VF; Sánchez-Sixto C; Castedo L; Canales A; Cañada FJ; Jiménez-Barbero J; Lamb H; Hawkins AR; González-Bello C
ChemMedChem; 2006 Sep; 1(9):990-6. PubMed ID: 16952136
[TBL] [Abstract][Full Text] [Related]
7. Progress in type II dehydroquinase inhibitors: from concept to practice.
González-Bello C; Castedo L
Med Res Rev; 2007 Mar; 27(2):177-208. PubMed ID: 17004270
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of new nanomolar competitive inhibitors of Helicobacter pylori type II dehydroquinase. Structural details of the role of the aromatic moieties with essential residues.
Prazeres VF; Tizón L; Otero JM; Guardado-Calvo P; Llamas-Saiz AL; van Raaij MJ; Castedo L; Lamb H; Hawkins AR; González-Bello C
J Med Chem; 2010 Jan; 53(1):191-200. PubMed ID: 19911771
[TBL] [Abstract][Full Text] [Related]
9. Conformationally constrained diketopimelic acid analogues as inhibitors of dihydrodipicolinate synthase.
Boughton BA; Dobson RC; Gerrard JA; Hutton CA
Bioorg Med Chem Lett; 2008 Jan; 18(2):460-3. PubMed ID: 18077163
[TBL] [Abstract][Full Text] [Related]
10. Nanomolar inhibition of type II dehydroquinase based on the enolate reaction mechanism.
Toscano MD; Payne RJ; Chiba A; Kerbarh O; Abell C
ChemMedChem; 2007 Jan; 2(1):101-12. PubMed ID: 17068841
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of types I and II dehydroquinase.
Le Sann C; Gower MA; Abell AD
Mini Rev Med Chem; 2004 Sep; 4(7):747-56. PubMed ID: 15379642
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of Helicobacter pylori type II dehydroquinase inhibitor complexes: new directions for inhibitor design.
Robinson DA; Stewart KA; Price NC; Chalk PA; Coggins JR; Lapthorn AJ
J Med Chem; 2006 Feb; 49(4):1282-90. PubMed ID: 16480265
[TBL] [Abstract][Full Text] [Related]
13. Comparative binding energy COMBINE analysis for understanding the binding determinants of type II dehydroquinase inhibitors.
Peón A; Coderch C; Gago F; González-Bello C
ChemMedChem; 2013 May; 8(5):740-7. PubMed ID: 23450741
[TBL] [Abstract][Full Text] [Related]
14. Nanomolar competitive inhibitors of Mycobacterium tuberculosis and Streptomyces coelicolor type II dehydroquinase.
Prazeres VF; Sánchez-Sixto C; Castedo L; Lamb H; Hawkins AR; Riboldi-Tunnicliffe A; Coggins JR; Lapthorn AJ; González-Bello C
ChemMedChem; 2007 Feb; 2(2):194-207. PubMed ID: 17245805
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of potent ene-yne inhibitors of type II dehydroquinases as tuberculosis drug leads.
Tran AT; Cergol KM; West NP; Randall EJ; Britton WJ; Bokhari SA; Ibrahim M; Lapthorn AJ; Payne RJ
ChemMedChem; 2011 Feb; 6(2):262-5. PubMed ID: 21275049
[No Abstract] [Full Text] [Related]
16. Irreversible inhibition of type I dehydroquinase by substrates for type II dehydroquinase.
Bello CG; Harris JM; Manthey MK; Coggins JR; Abell C
Bioorg Med Chem Lett; 2000 Mar; 10(5):407-9. PubMed ID: 10743936
[TBL] [Abstract][Full Text] [Related]
17. Understanding the key factors that control the inhibition of type II dehydroquinase by (2R)-2-benzyl-3-dehydroquinic acids.
Peón A; Otero JM; Tizón L; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Gago F; Castedo L; González-Bello C
ChemMedChem; 2010 Oct; 5(10):1726-33. PubMed ID: 20815012
[TBL] [Abstract][Full Text] [Related]
18. Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: capturing interactions with Asp48.
Wan ZK; Lee J; Xu W; Erbe DV; Joseph-McCarthy D; Follows BC; Zhang YL
Bioorg Med Chem Lett; 2006 Sep; 16(18):4941-5. PubMed ID: 16806920
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of bifunctional inhibitors of type II dehydroquinase.
Toscano MD; Frederickson M; Evans DP; Coggins JR; Abell C; González-Bello C
Org Biomol Chem; 2003 Jun; 1(12):2075-83. PubMed ID: 12945898
[TBL] [Abstract][Full Text] [Related]
20. Specific chemical modification of bacterial type I dehydroquinase--opportunities for drug discovery.
González-Bello C
Future Med Chem; 2015; 7(17):2371-83. PubMed ID: 26599605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
